Myriad Genetics Acquires Patent on Another Breast Cancer-Linked Gene
By Ayesha Ahmad,
BioNews
| 01. 23. 2012
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C.
Mark Capone, president of Myriad, said: 'This intellectual property will enhance our ability to provide patients and health care providers important information on a patient's predisposition to hereditary breast and ovarian cancer'.
Read more...
Image via Flickr.
Related Articles
By Emma McDonald Kennedy
| 11.24.2024
Gig work in childcare, nursing, and transportation; non-invasive prenatal testing; gene editing; and space expeditions can all be attributed to one mistaken, pervasive assumption: that “we can innovate our way out of the thorniest problems, including reproductive ones” (22). In Reproductive Labor and Innovation: Against the Tech Fix in an Era of Hype, feminist political theorist Jennifer Denbow demonstrates why the U.S. has put so much of its hopes, and its money, on technological “innovations”––and why that hasn’t addressed...
By Tamsin Metelerkamp, Daily Maverick | 11.18.2024
The National Health Research Ethics Council (NHREC) has confirmed that heritable human genome editing (HHGE) remains illegal in South Africa, after changes in the latest version of the South African Ethics in Health Research Guidelines sparked concern among researchers that...
By World Health Organization, World Health Organization | 11.20.2024
By Bernice Lottering, Gene Online | 11.08.2024
South Africa’s updated health-research ethics guidelines, which now include heritable human genome editing, have sparked concern among scientists. The revisions, made in May but only recently gaining attention, outline protocols for modifying genetic material in sperm, eggs, or embryos—changes that...
